"use strict";(self.webpackChunkbuild_back_better_breakdown=self.webpackChunkbuild_back_better_breakdown||[]).push([[2760],{3905:function(e,n,t){t.d(n,{Zo:function(){return h},kt:function(){return l}});var i=t(7294);function r(e,n,t){return n in e?Object.defineProperty(e,n,{value:t,enumerable:!0,configurable:!0,writable:!0}):e[n]=t,e}function a(e,n){var t=Object.keys(e);if(Object.getOwnPropertySymbols){var i=Object.getOwnPropertySymbols(e);n&&(i=i.filter((function(n){return Object.getOwnPropertyDescriptor(e,n).enumerable}))),t.push.apply(t,i)}return t}function o(e){for(var n=1;n<arguments.length;n++){var t=null!=arguments[n]?arguments[n]:{};n%2?a(Object(t),!0).forEach((function(n){r(e,n,t[n])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(t)):a(Object(t)).forEach((function(n){Object.defineProperty(e,n,Object.getOwnPropertyDescriptor(t,n))}))}return e}function s(e,n){if(null==e)return{};var t,i,r=function(e,n){if(null==e)return{};var t,i,r={},a=Object.keys(e);for(i=0;i<a.length;i++)t=a[i],n.indexOf(t)>=0||(r[t]=e[t]);return r}(e,n);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(i=0;i<a.length;i++)t=a[i],n.indexOf(t)>=0||Object.prototype.propertyIsEnumerable.call(e,t)&&(r[t]=e[t])}return r}var c=i.createContext({}),d=function(e){var n=i.useContext(c),t=n;return e&&(t="function"==typeof e?e(n):o(o({},n),e)),t},h=function(e){var n=d(e.components);return i.createElement(c.Provider,{value:n},e.children)},u={inlineCode:"code",wrapper:function(e){var n=e.children;return i.createElement(i.Fragment,{},n)}},p=i.forwardRef((function(e,n){var t=e.components,r=e.mdxType,a=e.originalType,c=e.parentName,h=s(e,["components","mdxType","originalType","parentName"]),p=d(t),l=r,f=p["".concat(c,".").concat(l)]||p[l]||u[l]||a;return t?i.createElement(f,o(o({ref:n},h),{},{components:t})):i.createElement(f,o({ref:n},h))}));function l(e,n){var t=arguments,r=n&&n.mdxType;if("string"==typeof e||r){var a=t.length,o=new Array(a);o[0]=p;var s={};for(var c in n)hasOwnProperty.call(n,c)&&(s[c]=n[c]);s.originalType=e,s.mdxType="string"==typeof e?e:r,o[1]=s;for(var d=2;d<a;d++)o[d]=t[d];return i.createElement.apply(null,o)}return i.createElement.apply(null,t)}p.displayName="MDXCreateElement"},1307:function(e,n,t){t.r(n),t.d(n,{frontMatter:function(){return s},contentTitle:function(){return c},metadata:function(){return d},toc:function(){return h},default:function(){return p}});var i=t(7462),r=t(3366),a=(t(7294),t(3905)),o=["components"],s={sidebar_position:1},c="Part 1 - Lowering Prices Through Fair Drug Price Negotiation",d={unversionedId:"title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1",id:"title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1",title:"Part 1 - Lowering Prices Through Fair Drug Price Negotiation",description:"SEC. 139001. PROVIDING FOR LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE",source:"@site/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1.md",sourceDirName:"title-13-committee-on-ways-and-means/title-13-subtitle-j",slug:"/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1",editUrl:"https://github.com/EdwardAngert/build-back-better-breakdown/tree/main/packages/create-docusaurus/templates/shared/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1.md",tags:[],version:"current",sidebarPosition:1,frontMatter:{sidebar_position:1},sidebar:"tutorialSidebar",previous:{title:"Part 5 - Other Provisions",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-i/title-13-subtitle-i-part-5"},next:{title:"Part 2 - Prescription Drug Inflation Rebates",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2"}},h=[],u={toc:h};function p(e){var n=e.components,t=(0,r.Z)(e,o);return(0,a.kt)("wrapper",(0,i.Z)({},u,t,{components:n,mdxType:"MDXLayout"}),(0,a.kt)("h1",{id:"part-1---lowering-prices-through-fair-drug-price-negotiation"},"Part 1 - Lowering Prices Through Fair Drug Price Negotiation"),(0,a.kt)("p",null,"SEC. 139001. PROVIDING FOR LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE\nSOURCE DRUGS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) Program To Lower Prices for Certain High-Priced Single Source \n")),(0,a.kt)("p",null,"Drugs.--Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is\namended by adding at the end the following new part:"),(0,a.kt)("p",null," ``PART E--FAIR PRICE NEGOTIATION PROGRAM TO LOWER PRICES FOR CERTAIN\nHIGH-PRICED SINGLE SOURCE DRUGS"),(0,a.kt)("p",null,"``SEC. 1191. ESTABLISHMENT OF PROGRAM."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--The Secretary shall establish a Fair Price \n")),(0,a.kt)("p",null,"Negotiation Program (in this part referred to as the ",(0,a.kt)("inlineCode",{parentName:"p"},"program'). Under \nthe program, with respect to each price applicability period, the \nSecretary shall--\n            ``(1) publish a list of selected drugs in accordance with \n        section 1192;\n            ``(2) enter into agreements with manufacturers of selected \n        drugs with respect to such period, in accordance with section \n        1193;\n            ``(3) negotiate and, if applicable, renegotiate maximum \n        fair prices for such selected drugs, in accordance with section \n        1194; and\n            ``(4) carry out the administrative duties described in \n        section 1196.\n    ``(b) Definitions Relating to Timing.--For purposes of this part:\n            ``(1) Initial price applicability year.--The term "),"initial\nprice applicability year' means a plan year (beginning with\nplan year 2025) or, if agreed to in an agreement under section\n1193 by the Secretary and manufacturer involved, a period of\nmore than one plan year (beginning on or after January 1,\n2025).\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) Price applicability period.--The term `price \n        applicability period' means, with respect to a drug, the period \n        beginning with the initial price applicability year with \n        respect to which such drug is a selected drug and ending with \n        the last plan year during which the drug is a selected drug.\n            "),"(3) Selected drug publication date.--The term ",(0,a.kt)("inlineCode",{parentName:"p"},"selected \n        drug publication date' means, with respect to each initial \n        price applicability year, April 15 of the plan year that begins \n        2 years prior to such year.\n            ``(4) Voluntary negotiation period.--The term "),"voluntary\nnegotiation period' means, with respect to an initial price\napplicability year with respect to a selected drug, the\nperiod--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) beginning on the sooner of--\n                            "),"(i) the date on which the manufacturer of\nthe drug and the Secretary enter into an\nagreement under section 1193 with respect to\nsuch drug; or\n",(0,a.kt)("inlineCode",{parentName:"p"},"(ii) June 15 following the selected drug \n                        publication date with respect to such selected \n                        drug; and\n                    "),"(B) ending on March 31 of the year that begins\none year prior to the initial price applicability year.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(c) Other Definitions.--For purposes of this part:\n            "),"(1) Fair price eligible individual.--The term ",(0,a.kt)("inlineCode",{parentName:"p"},"fair price \n        eligible individual' means, with respect to a selected drug--\n                    ``(A) in the case such drug is furnished or \n                dispensed to the individual at a pharmacy or by a mail \n                order service--\n                            ``(i) an individual who is enrolled under a \n                        prescription drug plan under part D of title \n                        XVIII or an MA-PD plan under part C of such \n                        title if coverage is provided under such plan \n                        for such selected drug; and\n                            ``(ii) an individual who is enrolled under \n                        a group health plan or health insurance \n                        coverage offered in the group or individual \n                        market (as such terms are defined in section \n                        2791 of the Public Health Service Act) with \n                        respect to which there is in effect an \n                        agreement with the Secretary under section 1197 \n                        with respect to such selected drug as so \n                        furnished or dispensed; and\n                    ``(B) in the case such drug is furnished or \n                administered to the individual by a hospital, \n                physician, or other provider of services or supplier--\n                            ``(i) an individual who is entitled to \n                        benefits under part A of title XVIII or \n                        enrolled under part B of such title if such \n                        selected drug is covered under the respective \n                        part; and\n                            ``(ii) an individual who is enrolled under \n                        a group health plan or health insurance \n                        coverage offered in the group or individual \n                        market (as such terms are defined in section \n                        2791 of the Public Health Service Act) with \n                        respect to which there is in effect an \n                        agreement with the Secretary under section 1197 \n                        with respect to such selected drug as so \n                        furnished or administered.\n            ``(2) Maximum fair price.--The term "),"maximum fair price'\nmeans, with respect to a plan year during a price applicability\nperiod and with respect to a selected drug (as defined in\nsection 1192(c)) with respect to such period, the price\npublished pursuant to section 1195 in the Federal Register for\nsuch drug and year.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) Average international market price defined.--\n                    "),"(A) In general.--The terms ",(0,a.kt)("inlineCode",{parentName:"p"},"average international \n                market price' and "),"AIM price' mean, with respect to a\ndrug, the average price (which shall be the net average\nprice, if practicable, and volume-weighted, if\npracticable) for a unit (as defined in paragraph (4))\nof the drug for sales of such drug (calculated across\ndifferent dosage forms and strengths of the drug and\nnot based on the specific formulation or package size\nor package type), as computed (as of the date of\npublication of such drug as a selected drug under\nsection 1192(a)) in all countries described in clause\n(ii) of subparagraph (B) that are applicable countries\n(as described in clause (i) of such subparagraph) with\nrespect to such drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) Applicable countries.--\n                            "),"(i) In general.--For purposes of\nsubparagraph (A), a country described in clause\n(ii) is an applicable country described in this\nclause with respect to a drug if there is\navailable an average price for any unit for the\ndrug for sales of such drug in such country.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(ii) Countries described.--For purposes \n                        of this paragraph, the following are countries \n                        described in this clause:\n                                    "),"(I) Australia.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(II) Canada.\n                                    "),"(III) France.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(IV) Germany.\n                                    "),"(V) Japan.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(VI) The United Kingdom.\n            "),"(4) Unit.--The term `unit' means, with respect to a drug,\nthe lowest identifiable quantity (such as a capsule or tablet,\nmilligram of molecules, or grams) of the drug that is\ndispensed."),(0,a.kt)("p",null,"``SEC. 1192. SELECTION OF NEGOTIATION-ELIGIBLE DRUGS AS SELECTED DRUGS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--Not later than the selected drug publication \n")),(0,a.kt)("p",null,"date with respect to an initial price applicability year, subject to\nsubsection (h), the Secretary shall select and publish in the Federal\nRegister a list of--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1)(A) with respect to an initial price applicability \n        year during 2025, at least 25 negotiation-eligible drugs \n        described in subparagraphs (A) and (B), but not subparagraph \n        (C), of subsection (d)(1) (or, with respect to an initial price \n        applicability year during such period beginning after 2025, the \n        maximum number (if such number is less than 25) of such \n        negotiation-eligible drugs for the year) with respect to such \n        year; and\n            "),"(B) with respect to an initial price applicability year\nduring 2026 or a subsequent year, at least 50 negotiation-\neligible drugs described in subparagraphs (A) and (B), but not\nsubparagraph (C), of subsection (d)(1) (or, with respect to an\ninitial price applicability year during such period, the\nmaximum number (if such number is less than 50) of such\nnegotiation-eligible drugs for the year) with respect to such\nyear;\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) all negotiation-eligible drugs described in \n        subparagraph (C) of such subsection with respect to such year; \n        and\n            "),"(3) all new-entrant negotiation-eligible drugs (as\ndefined in subsection (g)(1)) with respect to such year.\nEach drug published on the list pursuant to the previous sentence shall\nbe subject to the negotiation process under section 1194 for the\nvoluntary negotiation period with respect to such initial price\napplicability year (and the renegotiation process under such section as\napplicable for any subsequent year during the applicable price\napplicability period). In applying this subsection, any negotiation-\neligible drug that is selected under this subsection for an initial\nprice applicability year shall not count toward the required minimum\namount of drugs to be selected under paragraph (1) for any subsequent\nyear, including such a drug so selected that is subject to\nrenegotiation under section 1194.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Selection of Drugs.--In carrying out subsection (a)(1) the \nSecretary shall select for inclusion on the published list described in \nsubsection (a) with respect to a price applicability period, the \nnegotiation-eligible drugs that the Secretary projects will result in \nthe greatest savings to the Federal Government or fair price eligible \nindividuals during the price applicability period. In making this \nprojection of savings for drugs for which there is an AIM price for a \nprice applicability period, the savings shall be projected across \ndifferent dosage forms and strengths of the drugs and not based on the \nspecific formulation or package size or package type of the drugs, \ntaking into consideration both the volume of drugs for which payment is \nmade, to the extent such data is available, and the amount by which the \nnet price for the drugs exceeds the AIM price for the drugs.\n    "),"(c) Selected Drug.--For purposes of this part, each drug included\non the list published under subsection (a) with respect to an initial\nprice applicability year shall be referred to as a ",(0,a.kt)("inlineCode",{parentName:"p"},"selected drug' with \nrespect to such year and each subsequent plan year beginning before the \nfirst plan year beginning after the date on which the Secretary \ndetermines two or more drug products--\n            ``(1) are approved or licensed (as applicable)--\n                    ``(A) under section 505(j) of the Federal Food, \n                Drug, and Cosmetic Act using such drug as the listed \n                drug; or\n                    ``(B) under section 351(k) of the Public Health \n                Service Act using such drug as the reference product; \n                and\n            ``(2) continue to be marketed.\n    ``(d) Negotiation-Eligible Drug.--\n            ``(1) In general.--For purposes of this part, the term \n        "),"negotiation-eligible drug' means, with respect to the selected\ndrug publication date with respect to an initial price\napplicability year, a qualifying single source drug, as defined\nin subsection (e), that meets any of the following criteria:\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) Covered part d drugs.--The drug is among the \n                125 covered part D drugs (as defined in section 1860D-\n                2(e)) for which there was an estimated greatest net \n                spending under parts C and D of title XVIII, as \n                determined by the Secretary, during the most recent \n                plan year prior to such drug publication date for which \n                data are available.\n                    "),"(B) Other drugs.--The drug is among the 125 drugs\nfor which there was an estimated greatest net spending\nin the United States (including the 50 States, the\nDistrict of Columbia, and the territories of the United\nStates), as determined by the Secretary, during the\nmost recent plan year prior to such drug publication\ndate for which data are available.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(C) Insulin.--The drug is a qualifying single \n                source drug described in subsection (e)(3).\n            "),"(2) Clarification.--In determining whether a qualifying\nsingle source drug satisfies any of the criteria described in\nparagraph (1), the Secretary shall, to the extent practicable,\nuse data that is aggregated across dosage forms and strengths\nof the drug and not based on the specific formulation or\npackage size or package type of the drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) Publication.--Not later than the selected drug \n        publication date with respect to an initial price applicability \n        year, the Secretary shall publish in the Federal Register a \n        list of negotiation-eligible drugs with respect to such \n        selected drug publication date.\n    "),"(e) Qualifying Single Source Drug.--For purposes of this part,\nthe term ",(0,a.kt)("inlineCode",{parentName:"p"},"qualifying single source drug' means any of the following:\n            ``(1) Drug products.--A drug that--\n                    ``(A) is approved under section 505(c) of the \n                Federal Food, Drug, and Cosmetic Act and continues to \n                be marketed pursuant to such approval; and\n                    ``(B) is not the listed drug for any drug that is \n                approved and continues to be marketed under section \n                505(j) of such Act.\n            ``(2) Biological products.--A biological product that--\n                    ``(A) is licensed under section 351(a) of the \n                Public Health Service Act, including any product that \n                has been deemed to be licensed under section 351 of \n                such Act pursuant to section 7002(e)(4) of the \n                Biologics Price Competition and Innovation Act of 2009, \n                and continues to be marketed under section 351 of such \n                Act; and\n                    ``(B) is not the reference product for any \n                biological product that is licensed and continues to be \n                marketed under section 351(k) of such Act.\n            ``(3) Insulin product.--Notwithstanding paragraphs (1) and \n        (2), any insulin product that is approved under subsection (c) \n        or (j) of section 505 of the Federal Food, Drug, and Cosmetic \n        Act or licensed under subsection (a) or (k) of section 351 of \n        the Public Health Service Act and continues to be marketed \n        under such section 505 or 351, including any insulin product \n        that has been deemed to be licensed under section 351(a) of the \n        Public Health Service Act pursuant to section 7002(e)(4) of the \n        Biologics Price Competition and Innovation Act of 2009 and \n        continues to be marketed pursuant to such licensure.\nFor purposes of applying paragraphs (1) and (2), a drug or biological \nproduct that is marketed by the same sponsor or manufacturer (or an \naffiliate thereof or a cross-licensed producer or distributor) as the \nlisted drug or reference product described in such respective paragraph \nshall not be taken into consideration.\n    ``(f) Information on International Drug Prices.--For purposes of \ndetermining which negotiation-eligible drugs to select under subsection \n(a) and, in the case of such drugs that are selected drugs, to \ndetermine the maximum fair price for such a drug and whether such \nmaximum fair price should be renegotiated under section 1194, the \nSecretary shall use data relating to the AIM price with respect to such \ndrug as available or provided to the Secretary and shall on an ongoing \nbasis request from manufacturers of selected drugs information on the \nAIM price of such a drug.\n    ``(g) New-Entrant Negotiation-Eligible Drugs.--\n            ``(1) In general.--For purposes of this part, the term \n        "),"new-entrant negotiation-eligible drug' means, with respect to\nthe selected drug publication date with respect to an initial\nprice applicability year, a qualifying single source drug--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) that is first approved or licensed, as \n                described in paragraph (1), (2), or (3) of subsection \n                (e), as applicable, during the year preceding such \n                selected drug publication date; and\n                    "),"(B) that the Secretary determines under paragraph\n(2) is likely to be included as a negotiation-eligible\ndrug with respect to the subsequent selected drug\npublication date.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) Determination.--In the case of a qualifying single \n        source drug that meets the criteria described in subparagraph \n        (A) of paragraph (1), with respect to an initial price \n        applicability year, if the wholesale acquisition cost at which \n        such drug is first marketed in the United States is equal to or \n        greater than the median household income (as determined \n        according to the most recent data collected by the United \n        States Census Bureau), the Secretary shall determine before the \n        selected drug publication date with respect to the initial \n        price applicability year, if the drug is likely to be included \n        as a negotiation-eligible drug with respect to the subsequent \n        selected drug publication date, based on the projected spending \n        under title XVIII or in the United States on such drug. For \n        purposes of this paragraph the term `United States' includes \n        the 50 States, the District of Columbia, and the territories of \n        the United States.\n    "),"(h) Conflict of Interest.--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) In general.--In the case the Inspector General of the \n        Department of Health and Human Services determines the \n        Secretary has a conflict, with respect to a matter described in \n        paragraph (2), the individual described in paragraph (3) shall \n        carry out the duties of the Secretary under this part, with \n        respect to a negotiation-eligible drug, that would otherwise be \n        such a conflict.\n            "),"(2) Matter described.--A matter described in this\nparagraph is--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) a financial interest (as described in section \n                2635.402 of title 5, Code of Federal Regulations, as in \n                effect on the date of the enactment of this section, \n                (except for an interest described in subsection \n                (b)(2)(iv) of such section)) on the date of the \n                selected drug publication date, with respect the price \n                applicability year (as applicable);\n                    "),"(B) a personal or business relationship (as\ndescribed in section 2635.502 of such title) on the\ndate of the selected drug publication date, with\nrespect the price applicability year;\n",(0,a.kt)("inlineCode",{parentName:"p"},"(C) employment by a manufacturer of a \n                negotiation-eligible drug during the preceding 10-year \n                period beginning on the date of the selected drug \n                publication date, with respect to each price \n                applicability year; and\n                    "),"(D) any other matter the General Counsel\ndetermines appropriate.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) Individual described.--An individual described in \n        this paragraph is--\n                    "),"(A) the highest-ranking officer or employee of\nthe Department of Health and Human Services (as\ndetermined by the organizational chart of the\nDepartment) that does not have a conflict under this\nsubsection; and\n``(B) is nominated by the President and confirmed\nby the Senate with respect to the position."),(0,a.kt)("p",null,"``SEC. 1193. MANUFACTURER AGREEMENTS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--For purposes of section 1191(a)(2), the \n")),(0,a.kt)("p",null,"Secretary shall enter into agreements with manufacturers of selected\ndrugs with respect to a price applicability period, by not later than\nJune 15 following the selected drug publication date with respect to\nsuch selected drug, under which--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) during the voluntary negotiation period for the \n        initial price applicability year for the selected drug, the \n        Secretary and manufacturer, in accordance with section 1194, \n        negotiate to determine (and, by not later than the last date of \n        such period and in accordance with subsection (c), agree to) a \n        maximum fair price for such selected drug of the manufacturer \n        in order to provide access to such price--\n                    "),"(A) to fair price eligible individuals who with\nrespect to such drug are described in subparagraph (A)\nof section 1191(c)(1) and are furnished or dispensed\nsuch drug during, subject to subparagraph (2), the\nprice applicability period; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) to hospitals, physicians, and other providers \n                of services and suppliers with respect to fair price \n                eligible individuals who with respect to such drug are \n                described in subparagraph (B) of such section and are \n                furnished or administered such drug during, subject to \n                subparagraph (2), the price applicability period;\n            "),"(2) the Secretary and the manufacturer shall, in\naccordance with a process and during a period specified by the\nSecretary pursuant to rulemaking, renegotiate (and, by not\nlater than the last date of such period and in accordance with\nsubsection (c), agree to) the maximum fair price for such drug\nif the Secretary determines that there is a material change in\nany of the factors described in section 1194(d) relating to the\ndrug, including changes in the AIM price for such drug, in\norder to provide access to such maximum fair price (as so\nrenegotiated)--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) to fair price eligible individuals who with \n                respect to such drug are described in subparagraph (A) \n                of section 1191(c)(1) and are furnished or dispensed \n                such drug during any year during the price \n                applicability period (beginning after such \n                renegotiation) with respect to such selected drug; and\n                    "),"(B) to hospitals, physicians, and other providers\nof services and suppliers with respect to fair price\neligible individuals who with respect to such drug are\ndescribed in subparagraph (B) of such section and are\nfurnished or administered such drug during any year\ndescribed in subparagraph (A);\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) the maximum fair price (including as renegotiated \n        pursuant to paragraph (2)), with respect to such a selected \n        drug, shall be provided to fair price eligible individuals, who \n        with respect to such drug are described in subparagraph (A) of \n        section 1191(c)(1), at the pharmacy or by a mail order service \n        at the point-of-sale of such drug;\n            "),"(4) the manufacturer, subject to subsection (d), submits\nto the Secretary, in a form and manner specified by the\nSecretary--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) for the voluntary negotiation period for the \n                price applicability period (and, if applicable, before \n                any period of renegotiation specified pursuant to \n                paragraph (2)) with respect to such drug all \n                information that the Secretary requires to carry out \n                the negotiation (or renegotiation process) under this \n                part, including information described in section \n                1192(f) and section 1194(d)(1); and\n                    "),"(B) on an ongoing basis, information on changes\nin prices for such drug that would affect the AIM price\nfor such drug or otherwise provide a basis for\nrenegotiation of the maximum fair price for such drug\npursuant to paragraph (2);\n",(0,a.kt)("inlineCode",{parentName:"p"},"(5) the manufacturer agrees that in the case the selected \n        drug of a manufacturer is a drug described in subsection (c), \n        the manufacturer will, in accordance with such subsection, make \n        any payment required under such subsection with respect to such \n        drug; and\n            "),"(6) the manufacturer complies with requirements imposed\nby the Secretary for purposes of administering the program,\nincluding with respect to the duties described in section 1196.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Agreement in Effect Until Drug Is No Longer a Selected \nDrug.--An agreement entered into under this section shall be effective, \nwith respect to a drug, until such drug is no longer considered a \nselected drug under section 1192(c).\n    "),"(c) Special Rule for Certain Selected Drugs Without AIM Price.--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) In general.--In the case of a selected drug for which \n        there is no AIM price available with respect to the initial \n        price applicability year for such drug and for which an AIM \n        price becomes available beginning with respect to a subsequent \n        plan year during the price applicability period for such drug, \n        if the Secretary determines that the amount described in \n        paragraph (2)(A) for a unit of such drug is greater than the \n        amount described in paragraph (2)(B) for a unit of such drug, \n        then by not later than one year after the date of such \n        determination, the manufacturer of such selected drug shall pay \n        to the Treasury an amount equal to the product of--\n                    "),"(A) the difference between such amount described\nin paragraph (2)(A) for a unit of such drug and such\namount described in paragraph (2)(B) for a unit of such\ndrug; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) the number of units of such drug sold in the \n                United States, including the 50 States, the District of \n                Columbia, and the territories of the United States, \n                during the period described in paragraph (2)(B).\n            "),"(2) Amounts described.--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) Weighted average price before aim price \n                available.--For purposes of paragraph (1), the amount \n                described in this subparagraph for a selected drug \n                described in such paragraph, is the amount equal to the \n                weighted average manufacturer price (as defined in \n                section 1927(k)(1)) for such dosage strength and form \n                for the drug during the period beginning with the first \n                plan year for which the drug is included on the list of \n                negotiation-eligible drugs published under section \n                1192(d) and ending with the last plan year during the \n                price applicability period for such drug with respect \n                to which there is no AIM price available for such drug.\n                    "),"(B) Amount multiplier after aim price\navailable.--For purposes of paragraph (1), the amount\ndescribed in this subparagraph for a selected drug\ndescribed in such paragraph, is the amount equal to 200\npercent of the AIM price for such drug with respect to\nthe first plan year during the price applicability\nperiod for such drug with respect to which there is an\nAIM price available for such drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(d) Confidentiality of Information.--Information submitted to the \nSecretary under this part by a manufacturer of a selected drug that is \nproprietary information of such manufacturer (as determined by the \nSecretary) may be used only by the Secretary or disclosed to and used \nby the Comptroller General of the United States or the Medicare Payment \nAdvisory Commission for purposes of carrying out this part.\n    "),"(e) Regulations.--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) In general.--The Secretary shall, pursuant to \n        rulemaking, specify, in accordance with paragraph (2), the \n        information that must be submitted under subsection (a)(4).\n            "),"(2) Information specified.--Information described in\nparagraph (1), with respect to a selected drug, shall include\ninformation on sales of the drug (by the manufacturer of the\ndrug or by another entity under license or other agreement with\nthe manufacturer, with respect to the sales of such drug,\nregardless of the name under which the drug is sold) in any\nforeign country that is part of the AIM price. The Secretary\nshall verify, to the extent practicable, such sales from\nappropriate officials of the government of the foreign country\ninvolved.\n``(f) Compliance With Requirements for Administration of Program.--\nEach manufacturer with an agreement in effect under this section shall\ncomply with requirements imposed by the Secretary or a third party with\na contract under section 1196(c)(1), as applicable, for purposes of\nadministering the program."),(0,a.kt)("p",null,"``SEC. 1194. NEGOTIATION AND RENEGOTIATION PROCESS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--For purposes of this part, under an agreement \n")),(0,a.kt)("p",null,"under section 1193 between the Secretary and a manufacturer of a\nselected drug, with respect to the period for which such agreement is\nin effect and in accordance with subsections (b) and (c), the Secretary\nand the manufacturer--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) shall during the voluntary negotiation period with \n        respect to the initial price applicability year for such drug, \n        in accordance with this section, negotiate a maximum fair price \n        for such drug for the purpose described in section 1193(a)(1); \n        and\n            "),"(2) as applicable pursuant to section 1193(a)(2) and in\naccordance with the process specified pursuant to such section,\nrenegotiate such maximum fair price for such drug for the\npurpose described in such section.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Negotiating Methodology and Objective.--\n            "),"(1) In general.--The Secretary shall develop and use a\nconsistent methodology for negotiations under subsection (a)\nthat, in accordance with paragraph (2) and subject to paragraph\n(3), achieves the lowest maximum fair price for each selected\ndrug while appropriately rewarding innovation.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) Prioritizing factors.--In considering the factors \n        described in subsection (d) in negotiating (and, as applicable, \n        renegotiating) the maximum fair price for a selected drug, the \n        Secretary shall, to the extent practicable, consider all of the \n        available factors listed but shall prioritize the following \n        factors:\n                    "),"(A) Research and development costs.--The factor\ndescribed in paragraph (1)(A) of subsection (d).\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) Market data.--The factor described in \n                paragraph (1)(B) of such subsection.\n                    "),"(C) Unit costs of production and distribution.--\nThe factor described in paragraph (1)(C) of such\nsubsection.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(D) Comparison to existing therapeutic \n                alternatives.--The factor described in paragraph (2)(A) \n                of such subsection.\n            "),"(3) Requirement.--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) In general.--In negotiating the maximum fair \n                price of a selected drug, with respect to an initial \n                price applicability year for the selected drug, and, as \n                applicable, in renegotiating the maximum fair price for \n                such drug, with respect to a subsequent year during the \n                price applicability period for such drug, in the case \n                that the manufacturer of the selected drug offers under \n                the negotiation or renegotiation, as applicable, a \n                price for such drug that is not more than the target \n                price described in subparagraph (B) for such drug for \n                the respective year, the Secretary shall agree under \n                such negotiation or renegotiation, respectively, to \n                such offered price as the maximum fair price.\n                    "),"(B) Target price.--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(i) In general.--Subject to clause (ii), \n                        the target price described in this subparagraph \n                        for a selected drug with respect to a year, is \n                        the average price (which shall be the net \n                        average price, if practicable, and volume-\n                        weighted, if practicable) for a unit of such \n                        drug for sales of such drug, as computed \n                        (across different dosage forms and strengths of \n                        the drug and not based on the specific \n                        formulation or package size or package type of \n                        the drug) in the applicable country described \n                        in section 1191(c)(3)(B) with respect to such \n                        drug that, with respect to such year, has the \n                        lowest average price for such drug as compared \n                        to the average prices (as so computed) of such \n                        drug with respect to such year in the other \n                        applicable countries described in such section \n                        with respect to such drug.\n                            "),"(ii) Selected drugs without aim price.--\nIn applying this paragraph in the case of\nnegotiating the maximum fair price of a\nselected drug for which there is no AIM price\navailable with respect to the initial price\napplicability year for such drug, or, as\napplicable, renegotiating the maximum fair\nprice for such drug with respect to a\nsubsequent year during the price applicability\nperiod for such drug before the first plan year\nfor which there is an AIM price available for\nsuch drug, the target price described in this\nsubparagraph for such drug and respective year\nis the amount that is 80 percent of the average\nmanufacturer price (as defined in section\n1927(k)(1)) for such drug and year.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(c) Limitation.--\n            "),"(1) In general.--Subject to paragraph (2), the maximum\nfair price negotiated (including as renegotiated) under this\nsection for a selected drug, with respect to each plan year\nduring a price applicability period for such drug, shall not\nexceed 120 percent of the AIM price applicable to such drug\nwith respect to such year.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) Selected drugs without aim price.--In the case of a \n        selected drug for which there is no AIM price available with \n        respect to the initial price applicability year for such drug, \n        for each plan year during the price applicability period before \n        the first plan year for which there is an AIM price available \n        for such drug, the maximum fair price negotiated (including as \n        renegotiated) under this section for the selected drug shall \n        not exceed the amount equal to 85 percent of the average \n        manufacturer price for the drug with respect to such year.\n    "),"(d) Considerations.--For purposes of negotiating and, as\napplicable, renegotiating (including for purposes of determining\nwhether to renegotiate) the maximum fair price of a selected drug under\nthis part with the manufacturer of the drug, the Secretary, consistent\nwith subsection (b)(2), shall take into consideration the factors\ndescribed in paragraphs (1), (2), (3), and (5), and may take into\nconsideration the factor described in paragraph (4):\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) Manufacturer-specific information.--The following \n        information, including as submitted by the manufacturer:\n                    "),"(A) Research and development costs of the\nmanufacturer for the drug and the extent to which the\nmanufacturer has recouped research and development\ncosts.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) Market data for the drug, including the \n                distribution of sales across different programs and \n                purchasers and projected future revenues for the drug.\n                    "),"(C) Unit costs of production and distribution of\nthe drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(D) Prior Federal financial support for novel \n                therapeutic discovery and development with respect to \n                the drug.\n                    "),"(E) Data on patents and on existing and pending\nexclusivity for the drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(F) National sales data for the drug.\n                    "),"(G) Information on clinical trials for the drug\nin the United States or in applicable countries\ndescribed in section 1191(c)(3)(B).\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) Information on alternative products.--The following \n        information:\n                    "),"(A) The extent to which the drug represents a\ntherapeutic advance as compared to existing therapeutic\nalternatives and, to the extent such information is\navailable, the costs of such existing therapeutic\nalternatives.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) Information on approval by the Food and Drug \n                Administration of alternative drug products.\n                    "),"(C) Information on comparative effectiveness\nanalysis for such products, taking into consideration\nthe effects of such products on specific populations,\nsuch as individuals with disabilities, the elderly,\nterminally ill, children, and other patient\npopulations.\nIn considering information described in subparagraph (C), the\nSecretary shall not use evidence or findings from comparative\nclinical effectiveness research in a manner that treats\nextending the life of an elderly, disabled, or terminally ill\nindividual as of lower value than extending the life of an\nindividual who is younger, nondisabled, or not terminally ill.\nNothing in the previous sentence shall affect the application\nor consideration of an AIM price for a selected drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) Foreign sales information.--To the extent available \n        on a timely basis, including as provided by a manufacturer of \n        the selected drug or otherwise, information on sales of the \n        selected drug in each of the countries described in section \n        1191(c)(3)(B).\n            "),"(4) VA drug pricing information.--Information disclosed\nto the Secretary pursuant to subsection (f).\n",(0,a.kt)("inlineCode",{parentName:"p"},"(5) Additional information.--Information submitted to the \n        Secretary, in accordance with a process specified by the \n        Secretary, by other parties that are affected by the \n        establishment of a maximum fair price for the selected drug.\n    "),"(e) Request for Information.--For purposes of negotiating and, as\napplicable, renegotiating (including for purposes of determining\nwhether to renegotiate) the maximum fair price of a selected drug under\nthis part with the manufacturer of the drug, with respect to a price\napplicability period, and other relevant data for purposes of this\nsection--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) the Secretary shall, not later than the selected drug \n        publication date with respect to the initial price \n        applicability year of such period, request drug pricing \n        information from the manufacturer of such selected drug, \n        including information described in subsection (d)(1); and\n            "),"(2) by not later than October 1 following the selected\ndrug publication date, the manufacturer of such selected drug\nshall submit to the Secretary such requested information in\nsuch form and manner as the Secretary may require.\nThe Secretary shall request, from the manufacturer or others, such\nadditional information as may be needed to carry out the negotiation\nand renegotiation process under this section.\n``(f) Disclosure of Information.--For purposes of this part, the\nSecretary of Veterans Affairs may disclose to the Secretary of Health\nand Human Services the price of any negotiation-eligible drug that is\npurchased pursuant to section 8126 of title 38, United States Code."),(0,a.kt)("p",null,"``SEC. 1195. PUBLICATION OF MAXIMUM FAIR PRICES."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--With respect to an initial price applicability \n")),(0,a.kt)("p",null,"year and selected drug with respect to such year, not later than April\n1 of the plan year prior to such initial price applicability year, the\nSecretary shall publish in the Federal Register the maximum fair price\nfor such drug negotiated under this part with the manufacturer of such\ndrug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Updates.--\n            "),"(1) Subsequent year maximum fair prices.--For a selected\ndrug, for each plan year subsequent to the initial price\napplicability year for such drug with respect to which an\nagreement for such drug is in effect under section 1193, the\nSecretary shall publish in the Federal Register--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) subject to subparagraph (B), the amount equal \n                to the maximum fair price published for such drug for \n                the previous year, increased by the annual percentage \n                increase in the consumer price index for all urban \n                consumers (all items; U.S. city average) as of \n                September of such previous year; or\n                    "),"(B) in the case the maximum fair price for such\ndrug was renegotiated, for the first year for which\nsuch price as so renegotiated applies, such\nrenegotiated maximum fair price.\n``(2) Prices negotiated after deadline.--In the case of a\nselected drug with respect to an initial price applicability\nyear for which the maximum fair price is determined under this\npart after the date of publication under this section, the\nSecretary shall publish such maximum fair price in the Federal\nRegister by not later than 30 days after the date such maximum\nprice is so determined."),(0,a.kt)("p",null,"``SEC. 1196. ADMINISTRATIVE DUTIES; COORDINATION PROVISIONS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) Administrative Duties.--\n        ``(1) In general.--For purposes of section 1191, the \n    administrative duties described in this section are the \n    following:\n                ``(A) The establishment of procedures (including \n            through agreements with manufacturers under this part, \n            contracts with prescription drug plans under part D of \n            title XVIII and MA-PD plans under part C of such title, \n            and agreements under section 1197 with group health \n            plans and health insurance issuers of health insurance \n            coverage offered in the individual or group market) \n            under which the maximum fair price for a selected drug \n            is provided to fair price eligible individuals, who \n            with respect to such drug are described in subparagraph \n            (A) of section 1191(c)(1), at pharmacies or by mail \n            order service at the point-of-sale of the drug for the \n            applicable price period for such drug and providing \n            that such maximum fair price is used for determining \n            cost-sharing under such plans or coverage for the \n            selected drug.\n                ``(B) The establishment of procedures (including \n            through agreements with manufacturers under this part \n            and contracts with hospitals, physicians, and other \n            providers of services and suppliers and agreements \n            under section 1197 with group health plans and health \n            insurance issuers of health insurance coverage offered \n            in the individual or group market) under which, in the \n            case of a selected drug furnished or administered by \n            such a hospital, physician, or other provider of \n            services or supplier to fair price eligible individuals \n            (who with respect to such drug are described in \n            subparagraph (B) of section 1191(c)(1)), the maximum \n            fair price for the selected drug is provided to such \n            hospitals, physicians, and other providers of services \n            and suppliers (as applicable) with respect to such \n            individuals and providing that such maximum fair price \n            is used for determining cost-sharing under the \n            respective part, plan, or coverage for the selected \n            drug.\n                ``(C) The establishment of procedures (including \n            through agreements and contracts described in \n            subparagraphs (A) and (B)) to ensure that, not later \n            than 90 days after the dispensing of a selected drug to \n            a fair price eligible individual by a pharmacy or mail \n            order service, the pharmacy or mail order service is \n            reimbursed for an amount equal to the difference \n            between--\n                        ``(i) the lesser of--\n                                ``(I) the wholesale acquisition \n                            cost of the drug;\n                                ``(II) the national average drug \n                            acquisition cost of the drug; and\n                                ``(III) any other similar \n                            determination of pharmacy acquisition \n                            costs of the drug, as determined by the \n                            Secretary; and\n                        ``(ii) the maximum fair price for the drug.\n                ``(D) The establishment of procedures to ensure \n            that the maximum fair price for a selected drug is \n            applied before--\n                        ``(i) any coverage or financial assistance \n                    under other health benefit plans or programs \n                    that provide coverage or financial assistance \n                    for the purchase or provision of prescription \n                    drug coverage on behalf of fair price eligible \n                    individuals as the Secretary may specify; and\n                        ``(ii) any other discounts.\n                ``(E) The establishment of procedures to enter into \n            appropriate agreements and protocols for the ongoing \n            computation of AIM prices for selected drugs, \n            including, to the extent possible, to compute the AIM \n            price for selected drugs and including by providing \n            that the manufacturer of such a selected drug should \n            provide information for such computation not later than \n            3 months after the first date of the voluntary \n            negotiation period for such selected drug.\n                ``(F) The establishment of procedures to compute \n            and apply the maximum fair price across different \n            strengths and dosage forms of a selected drug and not \n            based on the specific formulation or package size or \n            package type of the drug.\n                ``(G) The establishment of procedures to negotiate \n            and apply the maximum fair price in a manner that does \n            not include any dispensing or similar fee.\n                ``(H) The establishment of procedures to carry out \n            the provisions of this part, as applicable, with \n            respect to--\n                        ``(i) fair price eligible individuals who \n                    are enrolled under a prescription drug plan \n                    under part D of title XVIII or an MA-PD plan \n                    under part C of such title;\n                        ``(ii) fair price eligible individuals who \n                    are enrolled under a group health plan or \n                    health insurance coverage offered by a health \n                    insurance issuer in the individual or group \n                    market with respect to which there is an \n                    agreement in effect under section 1197; and\n                        ``(iii) fair price eligible individuals who \n                    are entitled to benefits under part A of title \n                    XVIII or enrolled under part B of such title.\n                ``(I) The establishment of a negotiation process \n            and renegotiation process in accordance with section \n            1194, including a process for acquiring information \n            described in subsection (d) of such section and \n            determining amounts described in subsection (b) of such \n            section.\n                ``(J) The provision of a reasonable dispute \n            resolution mechanism to resolve disagreements between \n            manufacturers, fair price eligible individuals, and the \n            third party with a contract under subsection (c)(1).\n        ``(2) Monitoring compliance.--\n                ``(A) In general.--The Secretary shall monitor \n            compliance by a manufacturer with the terms of an \n            agreement under section 1193, including by establishing \n            a mechanism through which violations of such terms may \n            be reported.\n                ``(B) Notification.--If a third party with a \n            contract under subsection (c)(1) determines that the \n            manufacturer is not in compliance with such agreement, \n            the third party shall notify the Secretary of such \n            noncompliance for appropriate enforcement under section \n            4192 of the Internal Revenue Code of 1986 or section \n            1198, as applicable.\n``(b) Collection of Data.--\n        ``(1) From prescription drug plans and ma-pd plans.--The \n    Secretary may collect appropriate data from prescription drug \n    plans under part D of title XVIII and MA-PD plans under part C \n    of such title in a timeframe that allows for maximum fair \n    prices to be provided under this part for selected drugs.\n        ``(2) From health plans.--The Secretary may collect \n    appropriate data from group health plans or health insurance \n    issuers offering group or individual health insurance coverage \n    in a timeframe that allows for maximum fair prices to be \n    provided under this part for selected drugs.\n        ``(3) Coordination of data collection.--To the extent \n    feasible, as determined by the Secretary, the Secretary shall \n    ensure that data collected pursuant to this subsection is \n    coordinated with, and not duplicative of, other Federal data \n    collection efforts.\n``(c) Contract With Third Parties.--\n        ``(1) In general.--The Secretary may enter into a contract \n    with 1 or more third parties to administer the requirements \n    established by the Secretary in order to carry out this part. \n    At a minimum, the contract with a third party under the \n    preceding sentence shall require that the third party--\n                ``(A) receive and transmit information between the \n            Secretary, manufacturers, and other individuals or \n            entities the Secretary determines appropriate;\n                ``(B) receive, distribute, or facilitate the \n            distribution of funds of manufacturers to appropriate \n            individuals or entities in order to meet the \n            obligations of manufacturers under agreements under \n            this part;\n                ``(C) provide adequate and timely information to \n            manufacturers, consistent with the agreement with the \n            manufacturer under this part, as necessary for the \n            manufacturer to fulfill its obligations under this \n            part; and\n                ``(D) permit manufacturers to conduct periodic \n            audits, directly or through contracts, of the data and \n            information used by the third party to determine \n            discounts for applicable drugs of the manufacturer \n            under the program.\n        ``(2) Performance requirements.--The Secretary shall \n    establish performance requirements for a third party with a \n    contract under paragraph (1) and safeguards to protect the \n    independence and integrity of the activities carried out by the \n    third party under the program under this part.\n")),(0,a.kt)("p",null,"``SEC. 1197. VOLUNTARY PARTICIPATION BY OTHER HEALTH PLANS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) Agreement To Participate Under Program.--\n        ``(1) In general.--Subject to paragraph (2), under the \n    program under this part the Secretary shall be treated as \n    having in effect an agreement with a group health plan or \n    health insurance issuer offering group or individual health \n    insurance coverage (as such terms are defined in section 2791 \n    of the Public Health Service Act), with respect to a price \n    applicability period and a selected drug with respect to such \n    period--\n                ``(A) with respect to such selected drug furnished \n            or dispensed at a pharmacy or by mail order service if \n            coverage is provided under such plan or coverage during \n            such period for such selected drug as so furnished or \n            dispensed; and\n                ``(B) with respect to such selected drug furnished \n            or administered by a hospital, physician, or other \n            provider of services or supplier if coverage is \n            provided under such plan or coverage during such period \n            for such selected drug as so furnished or administered.\n        ``(2) Opting out of agreement.--The Secretary shall not be \n    treated as having in effect an agreement under the program \n    under this part with a group health plan or health insurance \n    issuer offering group or individual health insurance coverage \n    with respect to a price applicability period and a selected \n    drug with respect to such period if such a plan or issuer \n    affirmatively elects, through a process specified by the \n    Secretary, not to participate under the program with respect to \n    such period and drug.\n``(b) Publication of Election.--With respect to each price \n")),(0,a.kt)("p",null,"applicability period and each selected drug with respect to such\nperiod, the Secretary and the Secretary of Labor and the Secretary of\nthe Treasury, as applicable, shall make public a list of each group\nhealth plan and each health insurance issuer offering group or\nindividual health insurance coverage, with respect to which coverage is\nprovided under such plan or coverage for such drug, that has elected\nunder subsection (a) not to participate under the program with respect\nto such period and drug."),(0,a.kt)("p",null,"``SEC. 1198. CIVIL MONETARY PENALTY."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) Violations Relating to Offering of Maximum Fair Price.--Any \n")),(0,a.kt)("p",null,"manufacturer of a selected drug that has entered into an agreement\nunder section 1193, with respect to a plan year during the price\napplicability period for such drug, that does not provide access to a\nprice that is not more than the maximum fair price (or a lesser price)\nfor such drug for such year--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) to a fair price eligible individual who with respect \n        to such drug is described in subparagraph (A) of section \n        1191(c)(1) and who is furnished or dispensed such drug during \n        such year; or\n            "),"(2) to a hospital, physician, or other provider of\nservices or supplier with respect to fair price eligible\nindividuals who with respect to such drug is described in\nsubparagraph (B) of such section and is furnished or\nadministered such drug by such hospital, physician, or provider\nor supplier during such year;\nshall be subject to a civil monetary penalty equal to ten times the\namount equal to the difference between the price for such drug made\navailable for such year by such manufacturer with respect to such\nindividual or hospital, physician, provider, or supplier and the\nmaximum fair price for such drug for such year.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Violations of Certain Terms of Agreement.--Any manufacturer \nof a selected drug that has entered into an agreement under section \n1193, with respect to a plan year during the price applicability period \nfor such drug, that is in violation of a requirement imposed pursuant \nto section 1193(a)(6) shall be subject to a civil monetary penalty of \nnot more than $1,000,000 for each such violation.\n    "),"(c) Application.--The provisions of section 1128A (other than\nsubsections (a) and (b)) shall apply to a civil monetary penalty under\nthis section in the same manner as such provisions apply to a penalty\nor proceeding under section 1128A(a)."),(0,a.kt)("p",null,"``SEC. 1199. MISCELLANEOUS PROVISIONS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) Paperwork Reduction Act.--Chapter 35 of title 44, United \n")),(0,a.kt)("p",null,"States Code, shall not apply to data collected under this part.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Limitation on Judicial Review.--The following shall not be \nsubject to judicial review:\n            "),"(1) The selection of drugs for publication under section\n1192(a).\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) The determination of whether a drug is a negotiation-\n        eligible drug under section 1192(d).\n            "),"(3) The determination of the maximum fair price of a\nselected drug under section 1194.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(4) The determination of units of a drug for purposes of \n        section 1191(c)(3).\n    "),"(c) Coordination.--In carrying out this part with respect to\ngroup health plans or health insurance coverage offered in the group\nmarket that are subject to oversight by the Secretary of Labor or the\nSecretary of the Treasury, the Secretary of Health and Human Services\nshall coordinate with such respective Secretary.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(d) Data Sharing.--The Secretary shall share with the Secretary \nof the Treasury such information as is necessary to determine the tax \nimposed by section 4192 of the Internal Revenue Code of 1986.''.\n    (b) Application of Maximum Fair Prices and Conforming Amendments.--\n            (1) Under medicare.--\n                    (A) Application to payments under part b.--Section \n                1847A(b)(1)(B) of the Social Security Act (42 U.S.C. \n                1395w-3a(b)(1)(B)) is amended by inserting "),"or in the\ncase of such a drug or biological that is a selected\ndrug (as defined in section 1192(c)), with respect to a\nprice applicability period (as defined in section\n1191(b)(2)), 106 percent of the maximum fair price (as\ndefined in section 1191(c)(2)) applicable for such drug\nand a plan year during such period'' after ",(0,a.kt)("inlineCode",{parentName:"p"},"paragraph \n                (4)''.\n                    (B) Exception to part d non-interference.--Section \n                1860D-11(i) of the Social Security Act (42 U.S.C. \n                1395w-111(i)) is amended by inserting "),", except as\nprovided under part E of title XI'' after ",(0,a.kt)("inlineCode",{parentName:"p"},"the \n                Secretary''.\n                    (C) Application as negotiated price under part d.--\n                Section 1860D-2(d)(1) of the Social Security Act (42 \n                U.S.C. 1395w-102(d)(1)) is amended--\n                            (i) in subparagraph (B), by inserting "),",\nsubject to subparagraph (D),'' after\n",(0,a.kt)("inlineCode",{parentName:"p"},"negotiated prices''; and\n                            (ii) by adding at the end the following new \n                        subparagraph:\n                    "),"(D) Application of maximum fair price for\nselected drugs.--In applying this section, in the case\nof a covered part D drug that is a selected drug (as\ndefined in section 1192(c)), with respect to a price\napplicability period (as defined in section\n1191(b)(2)), the negotiated prices used for payment (as\ndescribed in this subsection) shall be the maximum fair\nprice (as defined in section 1191(c)(2)) for such drug\nand for each plan year during such period.''.\n(D) Information from prescription drug plans and\nma-pd plans required.--\n(i) Prescription drug plans.--Section\n1860D-12(b) of the Social Security Act (42\nU.S.C. 1395w-112(b)) is amended by adding at\nthe end the following new paragraph:\n",(0,a.kt)("inlineCode",{parentName:"p"},"(8) Provision of information related to maximum fair \n        prices.--Each contract entered into with a PDP sponsor under \n        this part with respect to a prescription drug plan offered by \n        such sponsor shall require the sponsor to provide information \n        to the Secretary as requested by the Secretary in accordance \n        with section 1196(b).''.\n                            (ii) MA-PD plans.--Section 1857(f)(3) of \n                        the Social Security Act (42 U.S.C. 1395w-\n                        27(f)(3)) is amended by adding at the end the \n                        following new subparagraph:\n                    "),"(E) Provision of information related to maximum\nfair prices.--Section 1860D-12(b)(8).''.\n(2) Under group health plans and health insurance\ncoverage.--\n(A) PHSA.--Part D of title XXVII of the Public\nHealth Service Act (42 U.S.C. 300gg-111 et seq.) is\namended by adding at the end the following new section:"),(0,a.kt)("p",null,"``SEC. 2799A-11. FAIR PRICE NEGOTIATION PROGRAM AND APPLICATION OF\nMAXIMUM FAIR PRICES."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--In the case of a group health plan or health \n")),(0,a.kt)("p",null,"insurance issuer offering group or individual health insurance coverage\nthat is treated under section 1197 of the Social Security Act as having\nin effect an agreement with the Secretary under the Fair Price\nNegotiation Program under part E of title XI of such Act, with respect\nto a price applicability period (as defined in section 1191(b) of such\nAct) and a selected drug (as defined in section 1192(c) of such Act)\nwith respect to such period with respect to which coverage is provided\nunder such plan or coverage--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) the provisions of such part shall apply--\n                    "),"(A) if coverage of such selected drug is provided\nunder such plan or coverage if the drug is furnished or\ndispensed at a pharmacy or by a mail order service, to\nthe plans or coverage offered by such plan or issuer,\nand to the individuals enrolled under such plans or\ncoverage, during such period, with respect to such\nselected drug, in the same manner as such provisions\napply to prescription drug plans and MA-PD plans, and\nto individuals enrolled under such prescription drug\nplans and MA-PD plans during such period; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) if coverage of such selected drug is provided \n                under such plan or coverage if the drug is furnished or \n                administered by a hospital, physician, or other \n                provider of services or supplier, to the plans or \n                coverage offered by such plan or issuers, to the \n                individuals enrolled under such plans or coverage, and \n                to hospitals, physicians, and other providers of \n                services and suppliers during such period, with respect \n                to such drug in the same manner as such provisions \n                apply to the Secretary, to individuals entitled to \n                benefits under part A of title XVIII or enrolled under \n                part B of such title, and to hospitals, physicians, and \n                other providers and suppliers participating under title \n                XVIII during such period;\n            "),"(2) the plan or issuer shall apply any cost-sharing\nresponsibilities under such plan or coverage, with respect to\nsuch selected drug, by substituting an amount not more than the\nmaximum fair price negotiated under such part E of title XI for\nsuch drug in lieu of the drug price upon which the cost-sharing\nwould have otherwise applied, and such cost-sharing\nresponsibilities with respect to such selected drug may not\nexceed such maximum fair price; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) the Secretary shall apply the provisions of such part \n        E to such plan, issuer, and coverage, such individuals so \n        enrolled in such plans and coverage, and such hospitals, \n        physicians, and other providers and suppliers participating in \n        such plans and coverage.\n    "),"(b) Notification Regarding Nonparticipation in Fair Price\nNegotiation Program.--A group health plan or a health insurance issuer\noffering group or individual health insurance coverage shall publicly\ndisclose in a manner and in accordance with a process specified by the\nSecretary any election made under section 1197 of the Social Security\nAct by the plan or issuer to not participate in the Fair Price\nNegotiation Program under part E of title XI of such Act with respect\nto a selected drug (as defined in section 1192(c) of such Act) for\nwhich coverage is provided under such plan or coverage before the\nbeginning of the plan year for which such election was made.''.\n(B) ERISA.--\n(i) In general.--Subpart B of part 7 of\nsubtitle B of title I of the Employee\nRetirement Income Security Act of 1974 (29\nU.S.C. 1181 et seq.) is amended by adding at\nthe end the following new section:"),(0,a.kt)("p",null,"``SEC. 726. FAIR PRICE NEGOTIATION PROGRAM AND APPLICATION OF MAXIMUM\nFAIR PRICES."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--In the case of a group health plan or health \n")),(0,a.kt)("p",null,"insurance issuer offering group health insurance coverage that is\ntreated under section 1197 of the Social Security Act as having in\neffect an agreement with the Secretary under the Fair Price Negotiation\nProgram under part E of title XI of such Act, with respect to a price\napplicability period (as defined in section 1191(b) of such Act) and a\nselected drug (as defined in section 1192(c) of such Act) with respect\nto such period with respect to which coverage is provided under such\nplan or coverage--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) the provisions of such part shall apply, as \n        applicable--\n                    "),"(A) if coverage of such selected drug is provided\nunder such plan or coverage if the drug is furnished or\ndispensed at a pharmacy or by a mail order service, to\nthe plans or coverage offered by such plan or issuer,\nand to the individuals enrolled under such plans or\ncoverage, during such period, with respect to such\nselected drug, in the same manner as such provisions\napply to prescription drug plans and MA-PD plans, and\nto individuals enrolled under such prescription drug\nplans and MA-PD plans during such period; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) if coverage of such selected drug is provided \n                under such plan or coverage if the drug is furnished or \n                administered by a hospital, physician, or other \n                provider of services or supplier, to the plans or \n                coverage offered by such plan or issuers, to the \n                individuals enrolled under such plans or coverage, and \n                to hospitals, physicians, and other providers of \n                services and suppliers during such period, with respect \n                to such drug in the same manner as such provisions \n                apply to the Secretary, to individuals entitled to \n                benefits under part A of title XVIII or enrolled under \n                part B of such title, and to hospitals, physicians, and \n                other providers and suppliers participating under title \n                XVIII during such period;\n            "),"(2) the plan or issuer shall apply any cost-sharing\nresponsibilities under such plan or coverage, with respect to\nsuch selected drug, by substituting an amount not more than the\nmaximum fair price negotiated under such part E of title XI for\nsuch drug in lieu of the drug price upon which the cost-sharing\nwould have otherwise applied, and such cost-sharing\nresponsibilities with respect to such selected drug may not\nexceed such maximum fair price; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) the Secretary shall apply the provisions of such part \n        E to such plan, issuer, and coverage, and such individuals so \n        enrolled in such plans.\n    "),"(b) Notification Regarding Nonparticipation in Fair Price\nNegotiation Program.--A group health plan or a health insurance issuer\noffering group health insurance coverage shall publicly disclose in a\nmanner and in accordance with a process specified by the Secretary any\nelection made under section 1197 of the Social Security Act by the plan\nor issuer to not participate in the Fair Price Negotiation Program\nunder part E of title XI of such Act with respect to a selected drug\n(as defined in section 1192(c) of such Act) for which coverage is\nprovided under such plan or coverage before the beginning of the plan\nyear for which such election was made.''.\n(ii) Application to retiree and certain\nsmall group health plans.--Section 732(a) of\nthe Employee Retirement Income Security Act of\n1974 (29 U.S.C. 1191a(a)) is amended by\nstriking ",(0,a.kt)("inlineCode",{parentName:"p"},"section 711'' and inserting \n                        "),"sections 711 and 726''.\n(iii) Clerical amendment.--The table of\nsections for subpart B of part 7 of subtitle B\nof title I of the Employee Retirement Income\nSecurity Act of 1974 is amended by adding at\nthe end the following:"),(0,a.kt)("p",null,"``Sec. 726. Fair Price Negotiation Program and application of maximum\nfair prices.''.\n(C) IRC.--\n(i) In general.--Subchapter B of chapter\n100 of the Internal Revenue Code of 1986 is\namended by adding at the end the following new\nsection:"),(0,a.kt)("p",null,"``SEC. 9826. FAIR PRICE NEGOTIATION PROGRAM AND APPLICATION OF MAXIMUM\nFAIR PRICES."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--In the case of a group health plan that is \n")),(0,a.kt)("p",null,"treated under section 1197 of the Social Security Act as having in\neffect an agreement with the Secretary under the Fair Price Negotiation\nProgram under part E of title XI of such Act, with respect to a price\napplicability period (as defined in section 1191(b) of such Act) and a\nselected drug (as defined in section 1192(c) of such Act) with respect\nto such period with respect to which coverage is provided under such\nplan--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) the provisions of such part shall apply, as \n        applicable--\n                    "),"(A) if coverage of such selected drug is provided\nunder such plan if the drug is furnished or dispensed\nat a pharmacy or by a mail order service, to the plan,\nand to the individuals enrolled under such plan during\nsuch period, with respect to such selected drug, in the\nsame manner as such provisions apply to prescription\ndrug plans and MA-PD plans, and to individuals enrolled\nunder such prescription drug plans and MA-PD plans\nduring such period; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(B) if coverage of such selected drug is provided \n                under such plan if the drug is furnished or \n                administered by a hospital, physician, or other \n                provider of services or supplier, to the plan, to the \n                individuals enrolled under such plan, and to hospitals, \n                physicians, and other providers of services and \n                suppliers during such period, with respect to such drug \n                in the same manner as such provisions apply to the \n                Secretary, to individuals entitled to benefits under \n                part A of title XVIII or enrolled under part B of such \n                title, and to hospitals, physicians, and other \n                providers and suppliers participating under title XVIII \n                during such period;\n            "),"(2) the plan shall apply any cost-sharing\nresponsibilities under such plan, with respect to such selected\ndrug, by substituting an amount not more than the maximum fair\nprice negotiated under such part E of title XI for such drug in\nlieu of the drug price upon which the cost-sharing would have\notherwise applied, and such cost-sharing responsibilities with\nrespect to such selected drug may not exceed such maximum fair\nprice; and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(3) the Secretary shall apply the provisions of such part \n        E to such plan and such individuals so enrolled in such plan.\n    "),"(b) Notification Regarding Nonparticipation in Fair Price\nNegotiation Program.--A group health plan shall publicly disclose in a\nmanner and in accordance with a process specified by the Secretary any\nelection made under section 1197 of the Social Security Act by the plan\nto not participate in the Fair Price Negotiation Program under part E\nof title XI of such Act with respect to a selected drug (as defined in\nsection 1192(c) of such Act) for which coverage is provided under such\nplan before the beginning of the plan year for which such election was\nmade.''.\n(ii) Application to retiree and certain\nsmall group health plans.--Section 9831(a)(2)\nof the Internal Revenue Code of 1986 is amended\nby inserting ",(0,a.kt)("inlineCode",{parentName:"p"},"other than with respect to \n                        section 9826,'' before "),"any group health\nplan''.\n(iii) Clerical amendment.--The table of\nsections for subchapter B of chapter 100 of\nsuch Code is amended by adding at the end the\nfollowing new item:"),(0,a.kt)("p",null,(0,a.kt)("inlineCode",{parentName:"p"},"Sec. 9826. Fair Price Negotiation Program and application of maximum \n                            fair prices.''.\n            (3) Fair price negotiation program prices included in best \n        price and amp.--Section 1927 of the Social Security Act (42 \n        U.S.C. 1396r-8) is amended--\n                    (A) in subsection (c)(1)(C)(ii)--\n                            (i) in subclause (III), by striking at the \n                        end "),"; and'';\n(ii) in subclause (IV), by striking at the\nend the period and inserting ",(0,a.kt)("inlineCode",{parentName:"p"},"; and''; and\n                            (iii) by adding at the end the following \n                        new subclause:\n                                    "),"(V) in the case of a rebate\nperiod and a covered outpatient drug\nthat is a selected drug (as defined in\nsection 1192(c)) during such rebate\nperiod, shall be inclusive of the price\nfor such drug made available from the\nmanufacturer during the rebate period\nby reason of application of part E of\ntitle XI to any wholesaler, retailer,\nprovider, health maintenance\norganization, nonprofit entity, or\ngovernmental entity within the United\nStates.''; and\n(B) in subsection (k)(1)(B), by adding at the end\nthe following new clause:\n",(0,a.kt)("inlineCode",{parentName:"p"},"(iii) Clarification.--Notwithstanding \n                        clause (i), in the case of a rebate period and \n                        a covered outpatient drug that is a selected \n                        drug (as defined in section 1192(c)) during \n                        such rebate period, any reduction in price paid \n                        during the rebate period to the manufacturer \n                        for the drug by a wholesaler or retail \n                        community pharmacy described in subparagraph \n                        (A) by reason of application of part E of title \n                        XI shall be included in the average \n                        manufacturer price for the covered outpatient \n                        drug.''.\n            (4) FEHBP.--Section 8902 of title 5, United States Code, is \n        amended by adding at the end the following:\n    "),"(p) A contract may not be made or a plan approved under this\nchapter with any carrier that has affirmatively elected, pursuant to\nsection 1197 of the Social Security Act, not to participate in the Fair\nPrice Negotiation Program established under section 1191 of such Act\nfor any selected drug (as that term is defined in section 1192(c) of\nsuch Act).''.\n(5) Option of secretary of veterans affairs to purchase\ncovered drugs at maximum fair prices.--Section 8126 of title\n38, United States Code, is amended--\n(A) in subsection (a)(2), by inserting ",(0,a.kt)("inlineCode",{parentName:"p"},", subject \n                to subsection (j),'' after "),"may not exceed'';\n(B) in subsection (d), in the matter preceding\nparagraph (1), by inserting ",(0,a.kt)("inlineCode",{parentName:"p"},", subject to subsection \n                (j)'' after "),"for the procurement of the drug''; and\n(C) by adding at the end the following new\nsubsection:\n",(0,a.kt)("inlineCode",{parentName:"p"},"(j)(1) In the case of a covered drug that is a selected drug, for \nany year during the price applicability period for such drug, if the \nSecretary determines that the maximum fair price of such drug for such \nyear is less than the price for such drug otherwise in effect pursuant \nto this section (including after application of any reduction under \nsubsection (a)(2) and any discount under subsection (c)), at the option \nof the Secretary, in lieu of the maximum price (determined after \napplication of the reduction under subsection (a)(2) and any discount \nunder subsection (c), as applicable) that would be permitted to be \ncharged during such year for such drug pursuant to this section without \napplication of this subsection, the maximum price permitted to be \ncharged during such year for such drug pursuant to this section shall \nbe such maximum fair price for such drug and year.\n    "),"(2) For purposes of this subsection:\n",(0,a.kt)("inlineCode",{parentName:"p"},"(A) The term `maximum fair price' means, with respect to \n        a selected drug and year during the price applicability period \n        for such drug, the maximum fair price (as defined in section \n        1191(c)(2) of the Social Security Act) for such drug and year.\n            "),"(B) The term ",(0,a.kt)("inlineCode",{parentName:"p"},"negotiation eligible drug' has the meaning \n        given such term in section 1192(d)(1) of the Social Security \n        Act.\n            ``(C) The term "),"price applicability period' has, with\nrespect to a selected drug, the meaning given such term in\nsection 1191(b)(2) of such Act.\n`",(0,a.kt)("inlineCode",{parentName:"p"},"(D) The term "),"selected drug' means, with respect to a\nyear, a drug that is a selected drug under section 1192(c) of\nsuch Act for such year.''."),(0,a.kt)("p",null,"SEC. 139002. SELECTED DRUG MANUFACTURER EXCISE TAX IMPOSED DURING\nNONCOMPLIANCE PERIODS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) In General.--Subchapter E of chapter 32 of the Internal Revenue \n")),(0,a.kt)("p",null,"Code of 1986 is amended by adding at the end the following new section:"),(0,a.kt)("p",null,"``SEC. 4192. SELECTED DRUGS DURING NONCOMPLIANCE PERIODS."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"``(a) In General.--There is hereby imposed on the sale by the \n")),(0,a.kt)("p",null,"manufacturer, producer, or importer of any selected drug during a day\ndescribed in subsection (b) a tax in an amount such that the applicable\npercentage is equal to the ratio of--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) such tax, divided by\n            "),"(2) the sum of such tax and the price for which so sold.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(b) Noncompliance Periods.--A day is described in this subsection \nwith respect to a selected drug if it is a day during one of the \nfollowing periods:\n            "),"(1) The period beginning on the June 16th immediately\nfollowing the selected drug publication date and ending on the\nfirst date during which the manufacturer of the drug has in\nplace an agreement described in subsection (a) of section 1193\nof the Social Security Act with respect to such drug.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) The period beginning on the April 1st immediately \n        following the June 16th described in paragraph (1) and ending \n        on the first date during which the manufacturer of the drug has \n        agreed to a maximum fair price under such agreement.\n            "),"(3) In the case of a selected drug with respect to which\nthe Secretary of Health and Human Services has specified a\nrenegotiation period under such agreement, the period beginning\non the first date after the last date of such renegotiation\nperiod and ending on the first date during which the\nmanufacturer of the drug has agreed to a renegotiated maximum\nfair price under such agreement.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(4) With respect to information that is required to be \n        submitted to the Secretary of Health and Human Services under \n        such agreement, the period beginning on the date on which such \n        Secretary certifies that such information is overdue and ending \n        on the date that such information is so submitted.\n            "),"(5) In the case of a selected drug with respect to which\na payment is due under subsection (c) of such section 1193, the\nperiod beginning on the date on which the Secretary of Health\nand Human Services certifies that such payment is overdue and\nending on the date that such payment is made in full.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(c) Applicable Percentage.--For purposes of this section, the \nterm `applicable percentage' means--\n            "),"(1) in the case of sales of a selected drug during the\nfirst 90 days described in subsection (b) with respect to such\ndrug, 65 percent,\n",(0,a.kt)("inlineCode",{parentName:"p"},"(2) in the case of sales of such drug during the 91st day \n        through the 180th day described in subsection (b) with respect \n        to such drug, 75 percent,\n            "),"(3) in the case of sales of such drug during the 181st\nday through the 270th day described in subsection (b) with\nrespect to such drug, 85 percent, and\n",(0,a.kt)("inlineCode",{parentName:"p"},"(4) in the case of sales of such drug during any \n        subsequent day, 95 percent.\n    "),"(d) Selected Drug.--For purposes of this section--\n",(0,a.kt)("inlineCode",{parentName:"p"},"(1) In general.--The term `selected drug' means any \n        selected drug (within the meaning of section 1192 of the Social \n        Security Act) which is manufactured or produced in the United \n        States or entered into the United States for consumption, use, \n        or warehousing.\n            "),"(2) United states.--The term ",(0,a.kt)("inlineCode",{parentName:"p"},"United States' has the \n        meaning given such term by section 4612(a)(4).\n            ``(3) Coordination with rules for possessions of the united \n        states.--Rules similar to the rules of paragraphs (2) and (4) \n        of section 4132(c) shall apply for purposes of this section.\n    ``(e) Other Definitions.--For purposes of this section, the terms \n"),"selected drug publication date' and `maximum fair price' have the\nmeaning given such terms in section 1191 of the Social Security Act.\n",(0,a.kt)("inlineCode",{parentName:"p"},"(f) Anti-Abuse Rule.--In the case of a sale which was timed for \nthe purpose of avoiding the tax imposed by this section, the Secretary \nmay treat such sale as occurring during a day described in subsection \n(b).''.\n    (b) No Deduction for Excise Tax Payments.--Section 275 of the \nInternal Revenue Code of 1986 is amended by adding "),"or by section\n4192'' before the period at the end of subsection (a)(6).\n(c) Conforming Amendments.--\n(1) Section 4221(a) of the Internal Revenue Code of 1986 is\namended by inserting ",(0,a.kt)("inlineCode",{parentName:"p"},"or 4192'' after "),"section 4191''.\n(2) Section 6416(b)(2) of such Code is amended by inserting\n",(0,a.kt)("inlineCode",{parentName:"p"},"or 4192'' after "),"section 4191''.\n(d) Clerical Amendments.--\n(1) The heading of subchapter E of chapter 32 of the\nInternal Revenue Code of 1986 is amended by striking ",(0,a.kt)("inlineCode",{parentName:"p"},"Medical \n        Devices'' and inserting "),"Other Medical Products''.\n(2) The table of subchapters for chapter 32 of such Code is\namended by striking the item relating to subchapter E and\ninserting the following new item:"),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"           ``subchapter e. other medical products''.\n\n        (3) The table of sections for subchapter E of chapter 32 of \n    such Code is amended by adding at the end the following new \n    item:\n")),(0,a.kt)("p",null,"``Sec. 4192. Selected drugs during noncompliance periods.''.\n(e) Effective Date.--The amendments made by this section shall\napply to sales after the date of the enactment of this Act."),(0,a.kt)("p",null,"SEC. 139003. FAIR PRICE NEGOTIATION IMPLEMENTATION FUND."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) In General.--There is hereby established a Fair Price \n")),(0,a.kt)("p",null,"Negotiation Implementation Fund (referred to in this section as the\n``Fund''). The Secretary of Health and Human Services may obligate and\nexpend amounts in the Fund to carry out this part and parts 2 and 3\n(and the amendments made by such parts).\n(b) Funding.--There is authorized to be appropriated, and there is\nhereby appropriated, out of any monies in the Treasury not otherwise\nappropriated, to the Fund $3,000,000,000, to remain available until\nexpended, of which--\n(1) $600,000,000 shall become available on the date of the\nenactment of this Act;\n(2) $600,000,000 shall become available on October 1, 2023;\n(3) $600,000,000 shall become available on October 1, 2024;\n(4) $600,000,000 shall become available on October 1, 2025;\nand\n(5) $600,000,000 shall become available on October 1, 2026.\n(c) Supplement Not Supplant.--Any amounts appropriated pursuant to\nthis section shall be in addition to any other amounts otherwise\nappropriated pursuant to any other provision of law."))}p.isMDXComponent=!0}}]);